Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | MTOR | P42345 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22466092 | 0.79 | AKR1C3 (0.46) | HTTLMNAMAPK1ALDH1A1KDM4E | |
| SCHEMBL3326479 | 0.79 | MTOR (0.43) | PIK3R1PIK3CAMTORALDH1A1TSHR | |
| SCHEMBL9418611 | 0.76 | HTT (0.61) | HTTLMNAPIK3R1PIK3CAMTOR | |
| SCHEMBL8973821 | 0.74 | HTT (0.63) | HTTLMNAPIK3R1PIK3CAMTOR | |
| SCHEMBL22466056 | 0.73 | DHFR (0.49) | HTTLMNAALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1873066 | 0.70 | POLB (0.58) | PIK3R1PIK3CAMTORMAPK1ALDH1A1 | |
| SCHEMBL2899743 | 0.69 | KDM4E (0.48) | HTTLMNAPIK3R1PIK3CAMTOR | |
| SCHEMBL3327130 | 0.69 | MTOR (0.62) | HTTLMNAPIK3CAMTORMAPK1 | |
| SCHEMBL1309817 | 0.68 | PIK3CA (0.55) | HTTPIK3R1PIK3CAMTORALDH1A1 | |
| SCHEMBL1989269 | 0.68 | MET (0.46) | HTTLMNAPIK3R1PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| EP-1877388-A2 | HYDRAZINOMETHYL, HYDRAZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | Kudos Pharmaceuticals Ltd (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20060199804-A1 | Compounds | KUDOS PHARMACEUTICALS LTD (GB) | 2006-09-07 | — | — | US | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199804-A1 | Compounds | CA4, CA6, CYP2B6 | HTT 4100/4885LMNA 2032/4885PIK3R1 3380/4885 |
| US-20100130473-A1 | COMPOUNDS | CA6, CYP2B6, CA4 | HTT 3799/4885LMNA 2245/4885PIK3R1 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.